NCT03989115: Dose-Escalation and Dose-Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors

NCT03989115
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER++, PR+
Other Mutations: RAS, RAF, NF1/2
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known or suspected leptomeningeal or brain metastases
https://ClinicalTrials.gov/show/NCT03989115

Comments are closed.

Up ↑